Eric A. Hughes Sells 52,742 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock

Key Points

• Teva Pharmaceutical Industries insider Eric A. Hughes sold 52,742 shares at an average price of $15.16, totaling approximately $799,568.72.
• The company's stock experienced a slight increase of 0.2%, reaching $15.72, while the stock has a 1-year range between $12.47 and $22.80.
• Several analysts have upgraded Teva's rating, with a consensus target price of $24.71 and a majority indicating a "buy" stance on the stock.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Teva Pharmaceutical Industries Stock Up 0.3%

TEVA stock traded up $0.05 during midday trading on Friday, reaching $16.34. 9,533,492 shares of the company were exchanged, compared to its average volume of 13,038,851. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The stock's 50-day simple moving average is $16.72 and its 200 day simple moving average is $16.39. The company has a market cap of $18.74 billion, a price-to-earnings ratio of -102.13, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. During the same quarter last year, the company earned $0.61 earnings per share. The firm's revenue for the quarter was up .3% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of TEVA. Itau Unibanco Holding S.A. acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $453,000. Intech Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 0.3% during the second quarter. Intech Investment Management LLC now owns 350,399 shares of the company's stock worth $5,873,000 after purchasing an additional 1,059 shares during the period. Creative Planning lifted its holdings in shares of Teva Pharmaceutical Industries by 23.8% during the second quarter. Creative Planning now owns 56,164 shares of the company's stock worth $941,000 after purchasing an additional 10,784 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 36.1% during the second quarter. SG Americas Securities LLC now owns 459,780 shares of the company's stock worth $7,706,000 after purchasing an additional 121,881 shares during the period. Finally, WealthShield Partners LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 6.6% during the second quarter. WealthShield Partners LLC now owns 15,996 shares of the company's stock worth $268,000 after purchasing an additional 996 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.